查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1578952

软组织肉瘤市场：按治疗类型、疾病类型、最终用户、治疗类型、分销管道 - 全球预测 2025-2030

Soft Tissue Sarcomas Market by Treatment Type, Disease Type, End User, Therapy Type, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年软组织肉瘤市场价值为67282万美元，预计2024年将达到73082万美元，复合年增长率为9.65%，到2030年将达到128282万美元。

软组织肉瘤 (STS) 代表出现在结缔组织中的多种恶性，包括肌肉、脂肪、神经和血管。这些肿瘤罕见且多样，需要准确的诊断和治疗方法。随着全球癌症发生率的不断上升，对先进的 STS 治疗技术和药物的需求至关重要。该市场涵盖全方位的诊断和治疗性介入，从 MRI 和 CT 成像到标靶治疗和手术方法。最终用途主要是医院、癌症研究机构和专科诊所。癌症发病率上升、诊断技术进步以及新药和治疗通讯协定的开发推动了市场成长。人工智慧与诊断的整合以及精准医疗的引入是未来有望成长的领域。生物技术创新，特别是基因组分析和免疫疗法，具有巨大的潜力。然而，该市场面临治疗成本高、监管障碍和药物核准复杂性等限制。另一个挑战是欠发达地区的STS管理意识和专业知识较低。为了利用新的机会，相关人员应专注于新型生物标誌物的研究和开发，利用人工智慧进行早期检测，并扩大有前景的治疗方法的临床试验。製药公司和研究机构之间的合作可以加速个人化医疗的突破。创新还可以致力于改进手术技术并最大限度地减少放射治疗和化疗的副作用。儘管存在这些挑战，STS 治疗仍然受到大量关注和投资。整体而言，STS 市场的特点是技术创新格局快速发展，具有充足的伙伴关係机会、技术进步和策略研究方向，以推动改善患者治疗结果和市场扩张。

主要市场统计
基准年[2023] 67282万美元
预测年份 [2024] 73082万美元
预测年份 [2030] 12,828.2 亿美元
复合年增长率（%） 9.65%

市场动态：快速发展的软组织肉瘤市场的关键市场洞察

软组织肉瘤市场正因供需的动态交互作用而转变。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 软组织肉瘤盛行率不断增加，导致对有效治疗的需求
    • 诊断工具的技术进步可提高早期检测率和患者治疗结果
    • 提高意识和政府努力促进软组织肉瘤的早期诊断和早期治疗
    • 对创新治疗方法的研发活动进行大量投资
  • 市场限制因素
    • 软组织肉瘤先进诊断工具的可用性有限且高成本
  • 市场机会
    • 扩大软组织肉瘤治疗的先进治疗选择
    • 加大软组织肉瘤治疗研发投入
    • 提高意识和早期诊断工作以改善软组织肉瘤患者的预后
  • 市场挑战
    • 由于软组织肉瘤治疗的分散性，全球范围内的治疗方法正在多样化。

波特的五力：驾驭软组织肉瘤市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更具弹性的市场定位。

PESTLE分析：了解软组织肉瘤市场的外部影响

外部宏观环境因素在塑造软组织肉瘤市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解软组织肉瘤市场的竞争格局

软组织肉瘤市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵软组织肉瘤市场供应商的绩效评估

FPNV定位矩阵是评估软组织肉瘤市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了软组织肉瘤市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，对软组织肉瘤市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 软组织肉瘤的流行增加了对有效治疗方法的需求
      • 诊断工具的技术进步提高了早期检测率和患者治疗结果
      • 意识的提高和政府的努力促进了软组织肉瘤的早期诊断和治疗
      • 对创新治疗方法的研发活动进行大量投资
    • 抑制因素
      • 软组织肉瘤的先进诊断工具可用性有限且成本高昂
    • 机会
      • 扩大软组织肉瘤治疗的先进治疗选择
      • 加大软组织肉瘤治疗研发投入
      • 提高意识提升和早期诊断工作以改善软组织肉瘤患者的预后
    • 任务
      • 软组织肉瘤治疗的片段化导致世界各地出现了多种治疗选择
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章依治疗类型分類的软组织肉瘤市场

  • 化疗
  • 联合治疗
  • 免疫疗法
  • 放射治疗
  • 外科手术
  • 标靶治疗

第七章软组织肉瘤市场：依疾病类型

  • 血管肉瘤
  • 透明细胞肉瘤
  • 促纤维增生性小圆细胞瘤
  • 伊文氏肉瘤
  • 胃肠道基质肿瘤
  • 平滑肌肉瘤
  • 脂肪肉瘤
    • 去分化脂肪肉瘤
    • 混合性脂肪肉瘤
    • 黏液样脂肪肉瘤
    • 多形性脂肪肉瘤
    • 高分化脂肪肉瘤
  • 恶性週边神经鞘瘤
  • 横纹肌肉瘤
    • 腺泡状横纹肌肉瘤
    • 未分化横纹肌肉瘤
    • 胚胎性横纹肌肉瘤
  • 滑膜肉瘤

第八章软组织肉瘤市场：依最终使用者分类

  • 门诊手术中心
  • 癌症治疗与研究中心
  • 诊所
  • 医院
    • 私立医院
    • 公立医院

第九章按治疗类型分類的软组织肉瘤市场

  • 一线治疗
  • 四线或更高级别的治疗
  • 二线治疗
  • 三线治疗

第10章软组织肉瘤市场：依通路

  • 医院药房
  • 网路药房
  • 零售药房

第十一章美洲软组织肉瘤市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太软组织肉瘤市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章欧洲、中东和非洲软组织肉瘤市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Bayer AG
  • Blueprint Medicines Corporation
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Daiichi Sankyo Company, Limited
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Ipsen Biopharmaceuticals, Inc.
  • Johnson & Johnson
  • Kyowa Kirin Co., Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-5D340F440B83

The Soft Tissue Sarcomas Market was valued at USD 672.82 million in 2023, expected to reach USD 730.82 million in 2024, and is projected to grow at a CAGR of 9.65%, to USD 1,282.82 million by 2030.

Soft Tissue Sarcomas (STS) represent a diverse group of malignant tumors that originate in the connective tissues, including muscles, fat, nerves, and blood vessels. These tumors are rare and diverse, demanding precise methods of diagnosis and treatment. With an increasing global burden of cancer, the need for advanced therapeutic techniques and pharmaceuticals for STS is critical. The market encompasses diagnostic and therapeutic interventions, involving everything from MRI and CT imaging to targeted therapies and surgical approaches. The end-use scope primarily spans hospitals, cancer research institutes, and specialized clinics. Market growth is driven by rising incidence rates of cancer, advancements in diagnostic technologies, and the development of novel drugs and treatment protocols. The integration of artificial intelligence with diagnostics and the adoption of precision medicine are promising areas for future growth. Biotech innovations, particularly in genomic analysis and immunotherapy, offer significant potential. However, the market faces limitations such as high treatment costs, regulatory hurdles, and the complexity in pharmaceutical approvals. Challenges also include limited awareness and expertise in STS management in underdeveloped regions. To leverage emerging opportunities, stakeholders should focus on research and development initiatives aimed at novel biomarkers, leveraging AI for early detection, and expanding clinical trials for promising therapeutic agents. Collaborations between pharmaceutical companies and research institutions can accelerate breakthroughs in personalized medicine. Innovation can also be directed towards improving surgical techniques and minimizing side effects of radiation and chemotherapy. Despite these challenges, STS therapies continue to attract significant attention and investment. Overall, the STS market is characterized by a burgeoning innovation landscape with ample opportunities for partnerships, technological advancements, and strategic research directions poised to improve patient outcomes and drive market expansion.

KEY MARKET STATISTICS
Base Year [2023] USD 672.82 million
Estimated Year [2024] USD 730.82 million
Forecast Year [2030] USD 1,282.82 million
CAGR (%) 9.65%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Soft Tissue Sarcomas Market

The Soft Tissue Sarcomas Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of soft tissue sarcomas leading to demand for effective treatments
    • Technological advancements in diagnostic tools improving early detection rates and patient outcomes
    • Rising awareness and government initiatives promoting early diagnosis and treatment of soft tissue sarcomas
    • Significant investments in research and development activities for innovative treatment options
  • Market Restraints
    • Limited availability and high cost of advanced diagnostic tools for soft tissue sarcomas
  • Market Opportunities
    • Expansion of advanced therapeutic options for soft tissue sarcoma treatment
    • Increasing investment in research and development for soft tissue sarcoma therapies
    • Rising awareness and early diagnosis initiatives to improve soft tissue sarcoma patient outcomes
  • Market Challenges
    • Fragmentation of soft tissue sarcoma treatment leading to varied management practices worldwide

Porter's Five Forces: A Strategic Tool for Navigating the Soft Tissue Sarcomas Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Soft Tissue Sarcomas Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Soft Tissue Sarcomas Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Soft Tissue Sarcomas Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Soft Tissue Sarcomas Market

A detailed market share analysis in the Soft Tissue Sarcomas Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Soft Tissue Sarcomas Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Soft Tissue Sarcomas Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Soft Tissue Sarcomas Market

A strategic analysis of the Soft Tissue Sarcomas Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Soft Tissue Sarcomas Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., AstraZeneca plc, Bayer AG, Blueprint Medicines Corporation, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo Company, Limited, Eisai Co., Ltd., Eli Lilly and Company, GlaxoSmithKline plc, Ipsen Biopharmaceuticals, Inc., Johnson & Johnson, Kyowa Kirin Co., Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., Roche Holding AG, Sanofi S.A., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Soft Tissue Sarcomas Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment Type, market is studied across Chemotherapy, Combination Therapy, Immunotherapy, Radiation Therapy, Surgery, and Targeted Therapy.
  • Based on Disease Type, market is studied across Angiosarcoma, Clear Cell Sarcoma, Desmoplastic Small-Round-Cell Tumor, Ewing's Sarcoma, Gastrointestinal Stromal Tumors, Leiomyosarcoma, Liposarcoma, Malignant Peripheral Nerve Sheath Tumors, Rhabdomyosarcoma, and Synovial Sarcoma. The Liposarcoma is further studied across Dedifferentiated Liposarcoma, Mixed-Type Liposarcoma, Myxoid Liposarcoma, Pleomorphic Liposarcoma, and Well-Differentiated Liposarcoma. The Rhabdomyosarcoma is further studied across Alveolar Rhabdomyosarcoma, Anaplastic Rhabdomyosarcoma, and Embryonal Rhabdomyosarcoma.
  • Based on End User, market is studied across Ambulatory Surgical Centers, Cancer Treatment and Research Centers, Clinics, and Hospitals. The Hospitals is further studied across Private Hospitals and Public Hospitals.
  • Based on Therapy Type, market is studied across First-Line Therapy, Fourth-Line Therapy and Above, Second-Line Therapy, and Third-Line Therapy.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of soft tissue sarcomas leading to demand for effective treatments
      • 5.1.1.2. Technological advancements in diagnostic tools improving early detection rates and patient outcomes
      • 5.1.1.3. Rising awareness and government initiatives promoting early diagnosis and treatment of soft tissue sarcomas
      • 5.1.1.4. Significant investments in research and development activities for innovative treatment options
    • 5.1.2. Restraints
      • 5.1.2.1. Limited availability and high cost of advanced diagnostic tools for soft tissue sarcomas
    • 5.1.3. Opportunities
      • 5.1.3.1. Expansion of advanced therapeutic options for soft tissue sarcoma treatment
      • 5.1.3.2. Increasing investment in research and development for soft tissue sarcoma therapies
      • 5.1.3.3. Rising awareness and early diagnosis initiatives to improve soft tissue sarcoma patient outcomes
    • 5.1.4. Challenges
      • 5.1.4.1. Fragmentation of soft tissue sarcoma treatment leading to varied management practices worldwide
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Soft Tissue Sarcomas Market, by Treatment Type

  • 6.1. Introduction
  • 6.2. Chemotherapy
  • 6.3. Combination Therapy
  • 6.4. Immunotherapy
  • 6.5. Radiation Therapy
  • 6.6. Surgery
  • 6.7. Targeted Therapy

7. Soft Tissue Sarcomas Market, by Disease Type

  • 7.1. Introduction
  • 7.2. Angiosarcoma
  • 7.3. Clear Cell Sarcoma
  • 7.4. Desmoplastic Small-Round-Cell Tumor
  • 7.5. Ewing's Sarcoma
  • 7.6. Gastrointestinal Stromal Tumors
  • 7.7. Leiomyosarcoma
  • 7.8. Liposarcoma
    • 7.8.1. Dedifferentiated Liposarcoma
    • 7.8.2. Mixed-Type Liposarcoma
    • 7.8.3. Myxoid Liposarcoma
    • 7.8.4. Pleomorphic Liposarcoma
    • 7.8.5. Well-Differentiated Liposarcoma
  • 7.9. Malignant Peripheral Nerve Sheath Tumors
  • 7.10. Rhabdomyosarcoma
    • 7.10.1. Alveolar Rhabdomyosarcoma
    • 7.10.2. Anaplastic Rhabdomyosarcoma
    • 7.10.3. Embryonal Rhabdomyosarcoma
  • 7.11. Synovial Sarcoma

8. Soft Tissue Sarcomas Market, by End User

  • 8.1. Introduction
  • 8.2. Ambulatory Surgical Centers
  • 8.3. Cancer Treatment and Research Centers
  • 8.4. Clinics
  • 8.5. Hospitals
    • 8.5.1. Private Hospitals
    • 8.5.2. Public Hospitals

9. Soft Tissue Sarcomas Market, by Therapy Type

  • 9.1. Introduction
  • 9.2. First-Line Therapy
  • 9.3. Fourth-Line Therapy and Above
  • 9.4. Second-Line Therapy
  • 9.5. Third-Line Therapy

10. Soft Tissue Sarcomas Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital Pharmacies
  • 10.3. Online Pharmacies
  • 10.4. Retail Pharmacies

11. Americas Soft Tissue Sarcomas Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Soft Tissue Sarcomas Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Soft Tissue Sarcomas Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Amgen Inc.
  • 3. AstraZeneca plc
  • 4. Bayer AG
  • 5. Blueprint Medicines Corporation
  • 6. Boehringer Ingelheim
  • 7. Bristol-Myers Squibb
  • 8. Daiichi Sankyo Company, Limited
  • 9. Eisai Co., Ltd.
  • 10. Eli Lilly and Company
  • 11. GlaxoSmithKline plc
  • 12. Ipsen Biopharmaceuticals, Inc.
  • 13. Johnson & Johnson
  • 14. Kyowa Kirin Co., Ltd.
  • 15. Merck & Co., Inc.
  • 16. Novartis AG
  • 17. Pfizer Inc.
  • 18. Roche Holding AG
  • 19. Sanofi S.A.
  • 20. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. SOFT TISSUE SARCOMAS MARKET RESEARCH PROCESS
  • FIGURE 2. SOFT TISSUE SARCOMAS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS SOFT TISSUE SARCOMAS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS SOFT TISSUE SARCOMAS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES SOFT TISSUE SARCOMAS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES SOFT TISSUE SARCOMAS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC SOFT TISSUE SARCOMAS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC SOFT TISSUE SARCOMAS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. SOFT TISSUE SARCOMAS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. SOFT TISSUE SARCOMAS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. SOFT TISSUE SARCOMAS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. SOFT TISSUE SARCOMAS MARKET DYNAMICS
  • TABLE 7. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY ANGIOSARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY CLEAR CELL SARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY DESMOPLASTIC SMALL-ROUND-CELL TUMOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY EWING'S SARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY LEIOMYOSARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY DEDIFFERENTIATED LIPOSARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY MIXED-TYPE LIPOSARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY MYXOID LIPOSARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY PLEOMORPHIC LIPOSARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY WELL-DIFFERENTIATED LIPOSARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY MALIGNANT PERIPHERAL NERVE SHEATH TUMORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY ALVEOLAR RHABDOMYOSARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY ANAPLASTIC RHABDOMYOSARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY EMBRYONAL RHABDOMYOSARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY SYNOVIAL SARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY CANCER TREATMENT AND RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY FIRST-LINE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY FOURTH-LINE THERAPY AND ABOVE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY SECOND-LINE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY THIRD-LINE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS SOFT TISSUE SARCOMAS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 61. ARGENTINA SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. ARGENTINA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. ARGENTINA SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 64. ARGENTINA SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 65. ARGENTINA SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 66. ARGENTINA SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 67. ARGENTINA SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. ARGENTINA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. BRAZIL SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. BRAZIL SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. BRAZIL SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 72. BRAZIL SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 73. BRAZIL SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 74. BRAZIL SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 75. BRAZIL SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. BRAZIL SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. CANADA SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. CANADA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. CANADA SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 80. CANADA SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 81. CANADA SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 82. CANADA SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 83. CANADA SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. CANADA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. MEXICO SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. MEXICO SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. MEXICO SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 88. MEXICO SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 89. MEXICO SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 90. MEXICO SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 91. MEXICO SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. MEXICO SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. UNITED STATES SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. UNITED STATES SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED STATES SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED STATES SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED STATES SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED STATES SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED STATES SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED STATES SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED STATES SOFT TISSUE SARCOMAS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC SOFT TISSUE SARCOMAS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 111. AUSTRALIA SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. AUSTRALIA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. AUSTRALIA SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 114. AUSTRALIA SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 115. AUSTRALIA SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 116. AUSTRALIA SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 117. AUSTRALIA SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. AUSTRALIA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 119. CHINA SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. CHINA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. CHINA SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 122. CHINA SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 123. CHINA SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 124. CHINA SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 125. CHINA SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. CHINA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 127. INDIA SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. INDIA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. INDIA SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 130. INDIA SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 131. INDIA SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 132. INDIA SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 133. INDIA SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. INDIA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 135. INDONESIA SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. INDONESIA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. INDONESIA SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 138. INDONESIA SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 139. INDONESIA SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 140. INDONESIA SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 141. INDONESIA SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. INDONESIA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 143. JAPAN SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. JAPAN SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. JAPAN SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 146. JAPAN SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 147. JAPAN SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 148. JAPAN SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 149. JAPAN SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. JAPAN SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 151. MALAYSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. MALAYSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. MALAYSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 154. MALAYSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 155. MALAYSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 156. MALAYSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 157. MALAYSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. MALAYSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 159. PHILIPPINES SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. PHILIPPINES SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. PHILIPPINES SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 162. PHILIPPINES SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 163. PHILIPPINES SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 164. PHILIPPINES SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 165. PHILIPPINES SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. PHILIPPINES SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 167. SINGAPORE SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. SINGAPORE SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SINGAPORE SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 170. SINGAPORE SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 171. SINGAPORE SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 172. SINGAPORE SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 173. SINGAPORE SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. SINGAPORE SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 175. SOUTH KOREA SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. SOUTH KOREA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. SOUTH KOREA SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 178. SOUTH KOREA SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 179. SOUTH KOREA SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 180. SOUTH KOREA SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 181. SOUTH KOREA SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. SOUTH KOREA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 183. TAIWAN SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. TAIWAN SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. TAIWAN SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 186. TAIWAN SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 187. TAIWAN SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 188. TAIWAN SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 189. TAIWAN SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. TAIWAN SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 191. THAILAND SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. THAILAND SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. THAILAND SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 194. THAILAND SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 195. THAILAND SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 196. THAILAND SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 197. THAILAND SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. THAILAND SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 199. VIETNAM SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. VIETNAM SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. VIETNAM SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 202. VIETNAM SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 203. VIETNAM SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 204. VIETNAM SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 205. VIETNAM SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. VIETNAM SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 216. DENMARK SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. DENMARK SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. DENMARK SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 219. DENMARK SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 220. DENMARK SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 221. DENMARK SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 222. DENMARK SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 223. DENMARK SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 224. EGYPT SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. EGYPT SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. EGYPT SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 227. EGYPT SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 228. EGYPT SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 229. EGYPT SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 230. EGYPT SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. EGYPT SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 232. FINLAND SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. FINLAND SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. FINLAND SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 235. FINLAND SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 236. FINLAND SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 237. FINLAND SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 238. FINLAND SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 239. FINLAND SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 240. FRANCE SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 241. FRANCE SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 242. FRANCE SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 243. FRANCE SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 244. FRANCE SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 245. FRANCE SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 246. FRANCE SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 247. FRANCE SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 248. GERMANY SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 249. GERMANY SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 250. GERMANY SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 251. GERMANY SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 252. GERMANY SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 253. GERMANY SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 254. GERMANY SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 255. GERMANY SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 256. ISRAEL SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 257. ISRAEL SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 258. ISRAEL SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 259. ISRAEL SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 260. ISRAEL SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 261. ISRAEL SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 262. ISRAEL SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 263. ISRAEL SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 264. ITALY SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 265. ITALY SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 266. ITALY SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 267. ITALY SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 268. ITALY SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 269. ITALY SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 270. ITALY SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 271. ITALY SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 272. NETHERLANDS SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 273. NETHERLANDS SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 274. NETHERLANDS SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 275. NETHERLANDS SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 276. NETHERLANDS SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 277. NETHERLANDS SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 278. NETHERLANDS SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 279. NETHERLANDS SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 280. NIGERIA SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 281. NIGERIA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 282. NIGERIA SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 283. NIGERIA SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 284. NIGERIA SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 285. NIGERIA SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 286. NIGERIA SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 287. NIGERIA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 288. NORWAY SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 289. NORWAY SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 290. NORWAY SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 291. NORWAY SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 292. NORWAY SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 293. NORWAY SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 294. NORWAY SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 295. NORWAY SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 296. POLAND SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 297. POLAND SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 298. POLAND SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 299. POLAND SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 300. POLAND SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 301. POLAND SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 302. POLAND SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 303. POLAND SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 304. QATAR SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 305. QATAR SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 306. QATAR SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 307. QATAR SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 308. QATAR SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 309. QATAR SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 310. QATAR SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 311. QATAR SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 312. RUSSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 313. RUSSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 314. RUSSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 315. RUSSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 316. RUSSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 317. RUSSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 318. RUSSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 319. RUSSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 320. SAUDI ARABIA SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 321. SAUDI ARABIA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 322. SAUDI ARABIA SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 323. SAUDI ARABIA SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 324. SAUDI ARABIA SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 325. SAUDI ARABIA SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 326. SAUDI ARABIA SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 327. SAUDI ARABIA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 328. SOUTH AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 329. SOUTH AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 330. SOUTH AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 331. SOUTH AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 332. SOUTH AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 333. SOUTH AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 334. SOUTH AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 335. SOUTH AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 336. SPAIN SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 337. SPAIN SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 338. SPAIN SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 339. S